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1.0 Introduction 
        The purpose of this project was to evaluate the efficacy of a newly developed 
10
B-containing 
compound - Cholesteryl carborane ester compound (or BCH) using human prostate cancer cells 
PC-3 for boron neutron capture therapy (NCT).  The BNCT is an experimental cancer treatment 
modality, which includes two sequential steps: (1) a thermal neutron absorbing agent (e.g. a 
10
B-
containing compound) is first administered into a patient, and (2) the tumor is then irradiated with 
thermal neutrons.  The compound is designed to preferentially enter the tumor cells.  During 
irradiation, a boron-10 atom in a tumor cell would absorb a thermal neutron and the energetic 
nuclear reaction products (i.e. the alpha particle and the lithium-7 ion) would subsequently kill 
the cell.  Because the therapeutic efficacy of BNCT highly depends on the effectiveness of the 
compound (i.e. its ability to preferentially enter tumor cells), each new compound must first be 
evaluated in cell cultures and small animals before it can be used for human clinical trials.  
The new 
10
B-containing compound (BCH) to be evaluated in this project was synthesized 
and provided by the University of Georgia Professor, Dr. Robert D. Lu (who now works at the 
FDA in Washington, D.C.).  It was thought that because BCH mimics the structure of native 
cholesteryl esters, it may be incorporated into the low density lipoprotein (LDL).   Earlier studies 
showed that BCH carried by liposomes resulted in an effective transfer of BCH into LDL in 
biological fluid and that the amount of BCH taken by the glioma cell lines (SF-767 and SF-763) 
was much more (up to 14 times) than that taken by the normal neuron cell line
1,2
.  Another recent 
study showed that prostate cancer cells also express more LDL receptors than normal prostate 
cells do in the presence of LDL or whole serum
3
.  As such, we believe that prostate cancer cells 
will also take up more BCH than the normal prostate cells do and that BCH has the potential to be 
used in a BNCT for treating human prostate cancer. 
The original proposal of this project included four major tasks: (1) to set up a new cell 
culture laboratory, (2) to prepare liposomal formulation with BCH and to maximize the uptake of 
BCH by the human prostate cancer cells (PC-3), (3) to quantitatively analyze the BCH (or 
10
B) 
uptake and egress of PC-3 cells, and (4) to irradiate the BCH-loaded prostate cancer cells with 
thermal neutrons and then conduct the cell survival analysis (i.e. the clonogenic assay).  Due to 
the nature of how BNCT works, the four tasks must go in sequence. 
2.0 Work Completed 
As previously reported
4
, while tasks (1) and (2) were completed in 2004, tasks (3) and (4) 
had to be delayed due to the remodeling of thermal column facility at the University of Maryland 
Training Reactor (MUTR) where the experiment was proposed to be carried out.  Consequently, 
the PI requested for no-cost extension of the project for the several years.  The remodeling of 
                                                                                                                                                
thermal column was finally completed in June 2007
5
, and the proposed experiment was then 
pursued at MUTR (see Attachment  A).  Unfortunately, as of today the researchers at MUTR 
have not yet produced reliable results for the BCH uptake to PC-3 cells.  They have found 
that extrusion restricts the amount of drug in the liposomal formulation due to membrane-
drug interaction and have now switched to a new method of making liposomes.  There 
are some preliminary indications that this new method will work much better. 
While the project is still being continued at MUTR at a slow pace (due to lack of 
funding), at this junction the PI can no longer expect that tasks (3) and (4) be completed 
in a timely manner.  As such, the PI would like to use Attachment A as the final report to 
conclude this project.  Should tasks (3) and (4) be completed in the future and if GCC is 
still interested in receiving the results, the PI will be happy to submit them to GCC. 
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 The use of a novel boron-containing cholesteryl carborane ester compound (BCH) 
with boron neutron capture therapy (BNCT) for the treatment of prostate cancer is under 
study.  Specifically, (1) the cellular uptake of this compound and (2) the efficiency of 
thermal neutron irradiation of cancerous prostate cells loaded with this compound are 
under investigation.  BCH is incorporated into a liposome formulation and analyzed with 
multi-angle light scattering to determine the size of the liposomes.  Boron-containing 
liposomes are then added to the cell growth medium of normal human prostate cells 
(RWPE-1) and cancer human prostate cells (PC-3), followed by analysis of BCH uptake 
and release with high performance liquid chromatography.  Variations in liposome BCH 
concentration and incubation time will determine the conditions for optimal therapeutic 
ratio.  Thermal neutron irradiation will be delivered through a newly designed plug 
within the 250 kW University of Maryland research reactor thermal column which allows 
environmental control throughout the irradiation.  Beam characterization and neutron 
spectrum unfolding will be completed to determine the dose rates within the sample 
chamber.  Cell survival fractions of normal and cancer human prostate cells will reveal 
the efficacy of this targeted radiotherapy.  Results from this project will assist in 
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I.  Introduction 
 According to the American Cancer Society, prostate cancer is the most frequently 
diagnosed cancer and the leading cause of cancer death in men.  It is estimated that 
218,890 new cases of prostate cancer occurred in the US during 2007, with 27,050 cases 
resulting in death.
1
  Because of this, the development of new treatment options involving 
targeted drug delivery which may improve the efficacy of prostate cancer treatment is 
essential.  
 The purpose of targeted drug delivery is to deliver more anti-cancer drug to 
cancer cells than to normal cells, resulting in fewer side effects for the cancer patient.  
One of the fundamental approaches is to design new anti-cancer compounds that 
capitalize on the differences between cancer and normal cells.  It has been reported that 
prostate cancer cells, like many other types of cancer cells, have high expression of low-
density lipoprotein (LDL) receptors in order to obtain more cholesterol to accelerate their 
characteristic abnormal growth.
2
  Therefore, targeted drug delivery can be accomplished 
by synthesizing cholesterol-based anti-cancer compounds specific to the LDL receptors.  
With this in mind, a new anti-cancer cholesteryl carborane ester compound (BCH) has 
been developed for testing.  This compound is designed to mimic the native cholesteryl 
esters in the human body and thus follow the same pathway to be selectively taken up by 




 This research will help to evaluate the ability of thermal neutron irradiation on 
prostate cancer cells containing the new carborane compound, BCH, to treat prostate 
cancer.  This compound has the potential to selectively target prostate cancer cells for 
boron neutron capture therapy (BNCT).  Specifically, (1) comparison between the 
cellular uptake and release of the new cholesteryl carborane compound in human normal 
and cancer cells and (2) examination of the efficacy of BNCT through neutron irradiation 
on human normal and cancer prostate cells loaded with BCH.  The results of this project 
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II.  Specific Aims 
 
 The objective of this research project is to investigate the efficacy of a new boron-
containing cholesteryl ester compound, BCH, as a targeting compound for BNCT of 
prostate cancer.  It is proposed that this compound will successfully target human prostate 
cancer cells and result in the radiation induced killing of cancer cells following the 
delivery of a dose of thermal neutrons.  In order to adequately determine this, the ability 
to prepare boron-containing liposomes, cellular uptake and release of the BCH, and cell 
survival following thermal irradiation must be studied. 
 First, incorporation of BCH into a liposomal formulation and subsequent 
liposome size distribution analysis must be completed.  To accomplish this task, 
liposomes with varying concentrations of BCH will be prepared by the thin film 
hydration method and extruded through membranes of various sizes.  Light scattering 
analysis will provide information regarding the size distribution of the liposomes as a 
function of BCH concentration and extrusion membrane size. 
 Second, the uptake and release kinetics of the BCH by the normal and cancer 
human prostate cells will the determined.  It is anticipated that the cholesterol seeking 
cancer cells expressing high levels of LDL receptors on their cell membranes will 
endocytose more BCH than the normal cells.  High performance liquid chromatography 
will be utilized to determine the cellular concentration of BCH in each cell population 
following various incubation times.  This data will indicate the time when peak BCH 
concentration is reached in the cancer cells, as well as providing release kinetics to ensure 
the BCH concentration remains high throughout the cell irradiation. 
 Third, cell survival assays must be performed following thermal neutron 
irradiation of the cells.  Cells containing boron will encounter high LET reactions 
resulting in fatal cell damage, while cells without BCH should be able to recover from the 
relatively low dose of thermal neutrons.  By irradiating when there is peak BCH 
concentration in the cancer cells, the potential for a fatal double stranded DNA break is at 
its highest. 
 Upon completion of these tasks, a detailed assessment of the efficacy as a 
potential BNCT drug for prostate cancer will be made. 
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III.  Technical Background 
 
Boron Neutron Capture Therapy 
 
 Boron neutron capture therapy (BNCT) is a binary radiation cancer treatment with 
potentially significant therapeutic advantages.  The treatment is based on specific cell 
killing by neutron irradiation of cancer cells that have been loaded with a boron-
containing compound.  The nuclear reaction between a thermal neutron (<0.025 eV) and 
a non-radioactive 
10












He + 2.4 MeV   (1)  
 
These high LET particles impart their energies in a relatively short range, approximately 
9 and 5 µm respectively.5  Because this distance is on the same scale as a typical cell 
diameter, the particles are capable of fatally damaging cells containing the 
10
B, while 
leaving neighboring cells unharmed.
6-8
  The 1.7 MeV α particles that result from this 
capture reaction have an average LET of 200 keV/µm, therefore capable of killing the 
cells when only a few particles deposit their energy.
9




FIGURE 1.  BNCT cell killing mechanism. 
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 It is important to note that hydrogen and nitrogen found within the normal tissue 
can also participate in capture reactions to produce gamma-rays and protons. 
 






H + γ 2.23 MeV    (2) 
 








p 0.63 MeV   (3) 
 
However, the thermal neutron cross sections of these atoms are very small (0.332 and 
1.75 barns, respectively) compared to that of 
10
B (3,838 barns) and will only deliver a 
small percentage of the overall dose.  
 There are several advantages of BNCT for targeted treatment.  (1) Because the 
boron-containing compounds themselves are neither required to be cytotoxic nor to 
release the anti-cancer units in the cells, boron conjugates can be designed solely for 
targeted delivery purposes.  (2) Radiation can be applied in a time window (radiation 
window) when the concentration ratio of boron-containing compounds in the cancer cells 
versus the surrounding normal tissue reaches a maximum.  (3) BNCT is particularly 
suitable for prostate cancer treatment because the physiological location of the prostate is 
distant from many vital organs, and can thus be targeted with a direct neutron beam.
5,7,10
  
In addition, the prostate lays 1.0-1.5 cm from the body surface and thus moderates an 




 Clinical trials for BNCT of glioblastoma multiforme (GBM) began in the 1950s at 
the Brookhaven National Laboratory (BNL) and the MIT reactor (MITR) and were 
stopped in 1961 due to disappointing outcomes.
12,13
  Analysis of the data showed that 
biodistribution studies and improved characterization of radiation sources were key 
factors that needed to be addressed.  Studies began again in Japan in 1967 using BPA as 
the boron-containing agent in combination with tumor “debulking”.  Thermal neutron 
beams were utilized that required the opening of the skull to increase neutron penetration 
and limit exposure to the skin.
14
  While failing to provide an increase in patient survival 
times, the results were promising compared to previous reports and trials began once 
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again in the USA and Europe in 1994.  The key difference in these trials was the use of 
epithermal neutron beams that would provide deeper tissue penetration while avoiding 
opening of the skull as performed in the Japanese trials.  The trials at BNL and MITR 
have been completed and produced results comparable to conventional photon 
therapies.
15
  Trials from Sweden and Finland have shown considerable increases in 
survival times compared to trials in the USA, although direct comparisons are difficult 
due to variations in therapy plans.  Other clinical trials are underway for BNCT treatment 
of melanomas, head and neck tumors, and colon adenocarcinoma.  A complete review of 




Design and Synthesis of Boron-containing Compounds 
 
 The overall success of BNCT lies in the ability to synthesize boron-containing 
compounds that satisfy the following requirements:  (1) selective targeting of cancer 




B atoms/cell or ~20-35 µg/g 
tumor, (3) tumor-to-normal tissue differential in the 3-5 range, (4) persistent cellular 
concentration of 
10
B throughout the irradiation procedure, and (5) low toxicity levels at 
doses required to attain adequate cellular concentrations.
7,17-19
   
 Currently, there are three boron-containing that are approved for clinical trials by 
the US Food and Drug Administration (FDA) with Investigational New Drug 
classification.  The first, borocaptate sodium Na2[closo-B12H11SH] (BSH), is a carborane 
derivative containing ten 
10
B atoms per molecule that has been used in BNCT treatment 
of GBM and its biodistribution in animals has been studied.
20-24
  The second, 4-
dihydroxyborylphenyl-alanine (BPA), is an amino acid containing one 
10
B atom per 
molecule that has been used to treat patients suffering from malignant melanoma and 
GBM, with similar studies in animal biodistribution.
25-30
  The third, polyhedral borane 
dianion [closo-B10H10]
2-
 (GB-10), has been studied for its ability to treat GBM.
31,32
  
However, each of these compounds has its own limitations in selective tumor targeting 
and retention leading to interest in the development of new compounds with the ability to 
better satisfy the criteria previously described.  A more complete discussion of these 
approved compounds can be found elsewhere.
5,33
  In addition to these FDA approved 
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drugs, many other compounds have been suggested as BNCT candidates including, but 
not limited to:  boronated porphyrins, boronated nucleosides and nucleotides, monoclonal 
antibodies, and growth factors.
5,7
  
 A promising new cholesteryl carborane ester compound (BCH) has been 
synthesized that mimics the structure of native cholesteryl ester but contains a carborane 
cage as the source of boron for BNCT.
3,4
  This compound will be evaluated in this 
research project for targeted therapy of prostate cancer.  The structure of BCH is shown 
in Figure 2. 
 
  
FIGURE 2.  Cholesteryl carborane esters in comparison with native cholesteryl esters. 
 
Similar to BSH, a boron cage is attached to the end of the molecule which contains ten 
10
B atoms.  In addition to this, the para-carborane cage increases the lipophilicity of the 
molecule which may improve incorporation of the molecule into the low density 
lipoproteins (LDL).
34-36
  Due to the high hydrophobicity of the BCH molecule, 
incorporation into a liposomal formulation is required for delivery into a biological 
system.
4
  Studies involving BCH uptake of normal neuron cells and brain glioma tumor 





TABLE 1.  Cellular uptake of BCH by different cell lines. 
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Targeted Drug Delivery 
  
 The true success of BNCT rests in the ability to specifically target cancer cells for 
delivery of boron while limiting the uptake of boron by normal cells.  Methods to address 
this issue include synthesis of individually targeting boron-containing compounds, 
conjugation of boron-containing compounds to macromolecules, and encapsulation of the 
compounds in microcapsules.
5,7
  However, complications have arisen in each case which 
make them less than ideal for adequate delivery of 
10
B to the targeted cells.   
 Another method for targeted delivery of 
10
B to cancer cells is based on the over-
expression of low-density lipoprotein (LDL) receptors by a variety of cancer cells.
38,39
  
Specifically, it has been reported that human prostate cancer cells (PC-3) lack the 
feedback regulation of LDL receptors seen in normal human prostate cells.
2
  LDL is a 20-
25 nm particle consisting of a lipid monolayer containing apolipoprotein that binds to 
LDL receptors, surrounding approximately 1,500 cholesteryl esters within its 
hydrophobic core.  LDL is the primary carrier of cholesterol in the blood stream and 
accounts for up to 90% of cholesterol found in the cell, the rest resulting from de novo 
synthesis.
40
   
 
 
FIGURE 3.  Low-density lipoprotein. 
 
LDL receptors are more active in rapidly dividing cancer cells because the formation of 
new cell membranes requires high levels of cholesterol.  The pathway for cellular uptake 
of LDL is termed receptor-mediated endocytosis and relies on cellular synthesis of 
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transmembrane LDL receptors that are expressed on the cell surface.  Once LDL binds to 
the receptor, the particle is endocytosed into the cell and transported to the lysosomes, 
where the LDL particles are hydrolyzed to form free cholesterol that can be used by the 
cells.  In normally functioning cells, feedback regulation prevents expression of LDL 
receptors on the cell surface once enough cholesterol has been accumulated within the 
cell.  In cancer cells however, this feedback is not present and cells will continue to 
endcytose LDL.  Therefore, successfully incorporating BCH into LDL will provide a 
means of not only preferentially targeting cancer cells but also facilitating intracellular 
delivery of the boron. 
 In order to introduce BCH into the LDL, the extremely hydrophobic compound 
must be incorporated into multi-lamellar vesicles (MLVs).  The MLV liposomes contain 
a mixture of DL-α-dipalmitoylphosphatidylcholine, cholesterol, and BCH.  As described 
later in detail, the compounds are mixed and dried to form a thin film which is then 
hydrated and agitated to form the MLVs. 
 
 
FIGURE 4.  Mechanism of vesicle formation (Avanti Polar Lipids, Inc.). 
 
Following extrusion through a membrane, the MLVs mix with LDL in the cell medium.  
The liposomes provide a means of solubilizing the BCH and facilitate interaction with the 
LDL.  Liposomes are able to interact with LDL through mechanisms of fusion, lipid 
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transfer, and lipid exchange because they are both lipid based particles, creating an 
efficient means of loading hydrophobic drugs into LDL.
35,37,41,42
  The uptake of BCH 
through the LDL pathway has been demonstrated in glioma cell lines using anit-LDL 






TABLE 2.  BCH uptake through the lipoprotein endocytosis pathway.   
                    * Lipoprotein deficient serum used in the culture medium. 
 
Thermal Neutron Irradiation 
 
 An area of importance for the success of BNCT is the availability of a thermal 
neutron source.  There is great interest in the development of accelerator based neutron 
sources for use in hospital settings, however to date there is no such setup.  Development 
of this type of neutron source would be a landmark step in the clinical application of 
BNCT and is discussed in great detail elsewhere.
6,7,43,44
  Currently, nuclear reactors are 
the only viable source of neutrons for BNCT.  Within the reactor core, neutrons are born 
from 
235
U fission with energy ranging from fast (>1 eV), to epithermal (0.025-1 eV), to 
thermal (<0.025 eV).  In order to improve the probability of interaction between neutrons 
and boron atoms within the cell, neutrons must be thermalized prior to capture by 
10
B.  
This occurs by interaction with a moderator, causing neutrons to lose energy through 
collisions with other atoms.  For clinical therapy, thermal neutrons that are incident upon 
the patient do not carry enough energy to penetrate the tissue to the tumor depth.  To 
resolve this problem, clinical sites are currently investigating the use of epithermal 
neutron beams that are moderated as they penetrate tissue, becoming thermal upon 
interaction with the tumor.
45,46
  Epithermal neutron beams are being utilized for BNCT 
therapy at reactors within the US at BNL and the MITR.  In addition to this, reactors in 
The Netherlands, Finland, Sweden, the Czech Republic, and Japan are modifying reactors 
for research involving BNCT.
6
  However, for research in an in vitro setting the 
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development of thermal neutron beams is of significant importance.  Clearly, 
monoenergetic neutron beams are unrealistic and will always be contaminated with 
higher energy neutrons and gamma rays which lead to non-specific cell killing; but by 
increasing shielding and beam moderation a higher proportion of incident radiation is 
delivered by thermal neutrons. 
 The 250 kW TRIGA Maryland University Training Reactor (MUTR) will be used 
as the thermal neutron irradiation source.  The core of the MUTR contains 93 fuel 
elements with UZrH fuel enriched to <20% and three borated carbide control rods.  The 
schematic of the core is shown in Figure 5. 
 
 
FIGURE 5.  MUTR core. 
 
 The thermal column (TC) experimental facility will be utilized for the in vitro 
irradiations.  The TC is a graphite filled housing extending from within the back face of the 
core through the pool tank wall and the concrete shield.  The core end of the housing is a 
0.953 cm (0.375 in) thick aluminum sleeve that passes through an aluminum nozzle welded 
to the pool tank wall.  The liner extends through the concrete shield and accommodates a 





) graphite stringers arranged to form a stepped column 1.52 m (5 ft) long.  The section 
forward of the step is 0.959 m (37.75 in) long and 0.610 m (2 ft) wide in which the 
stringers are arranged in a 6 x 6 pattern.  The outer section of the graphite column is 0.565 
m (22.25 in) long and 0.813 m (32 in) wide and its stringers are arranged in an 8 x 8 pattern 
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surrounded with 0.318 cm (0.125 in) thick boral.  Lead bricks surround the outer end of the 
TC graphite for shielding of gamma rays.   
 
 
FIGURE 6.  MUTR thermal column experimental facility. 
 
Thermal neutron flux measurements must be made when operating at various power levels 
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 Human normal prostate RWPE-1 cells (ATCC, Manassas, VA) are grown in 
Keratinocyte Serum Free Media supplemented with 0.05 mg/mL bovine pituitary extract 
and 5 ng/mL epidermal growth factor (Invitrogen, Carlsbad, CA) at 37
o
C in 5% CO2 in 
air, and in 75 cm
2 
tissue culture flasks (Thermo Fisher Scientific).  Human cancerous 
prostate PC-3 cells (ATCC, Manassas, VA) are grown in Ham’s F12 medium 
supplemented with 2 mM L-glutamine, 1.5 g/L sodium bicarbonate, and 10% fetal bovine 
serum at 37
o
C in 5% CO2 in air, and in 75 cm
2
 tissue culture flasks (Thermo Fisher 
Scientific). 
 
Preparation and Analysis of Liposomal Formulation 
 
 Liposomes are prepared using DL-α-dipalmitoylphosphatidylcholine (DPPC) and 
cholesterol (CHOL) (Sigma Aldrich).  DPPC and CHOL are added to a 5 mL round 
bottom flask in a molar ratio of 0.75:0.25, respectively.  Specifically, 56.9 mg DPPC and 
10 mg CHOL dissolved in chloroform are added.  The lipids are then dissolved in 3 mL 
of a 2:1 (v/v) chloroform-methanol mixture in the round bottom flask.  BCH is then 
added to the mixture in concentration of 10, 15, and 20 mM.  A heat gun is used to 
initiate evaporation of the solvents while turning the flask so that a thin layer of dried 
lipids is formed on the flask wall.  Following this initial drying, the flask is placed in a 
vacuum desiccator for at least 12 hours.  The flask is then removed from the vacuum and 
the dried lipids are hydrated with 5 mL of preheated PBS on a stirring hot plate for 30 
min.  Throughout the hydration process, the mixture is kept above 50
o
C to avoid falling 
below the phase transition temperature (Tm) of the lipids.  Once hydrated, the MLVs are 
allowed to mature for 1 hour at room temperature.  Size reduction of the MLVs is 
performed by passing the hydrated solution at least 10 times through an Avanti Mini-
Extruder with 50 and 80 nm extrusion membranes in 250 µL syringes (Avanti Polar 
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Lipids, Alabaster, AL) heated on a block to above 50
o
C.  Each 250 µL sample is 
collected separately and taken for size analysis.  
 
  
FIGURE 7.  Drying and extrusion of liposomal formulation (Avanti Polar Lipids). 
 
 Liposome samples are then take to the National Institute of Standards and 
Technology (NIST) for light scattering analysis using DAWN EOS multi-angle light 
scattering (MALS), Eclipse 2 Separation System particle separation, and ASTRA 
software (Wyatt Technology, Santa Barbara, CA).  Liposome solutions are diluted to 
50µg/100µL in PBS buffer with 200 ppm NaN3.  Samples are then placed in vials and 












1 mL/min 100 µL 0.5 to 0 
mL/min in 
30 min. 
350 µm 15 min. 63 min. 
TABLE 3.  Settings used for AFFF separation. 
 
The sample is then separated by size using asymmetric field flow fractionation (AFFF).  
Separation is achieved as the sample flows through a chamber that is exposed to a 
perpendicular cross flow as shown below. 
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FIGURE 8.  AFFF size separation (Wyatt Technology). 
 
Within the channel a parabolic flow profile is created that pushes particles closer to the 
walls of the chamber at a slower rate than those found in the center of the channel.  The 
introduction of a downward cross flow causes the larger particles to move closer to the 
lower chamber wall, thus positioning them in a slower flow than smaller particles that 
experience less drag from the cross flow.  As the particles move along the channel, 
smaller particles reach the outflow faster and are sent to the detector first. 
 As the MLVs pass through the 690 nm beam, the light is scattered and its angular 
dependence is monitored by eighteen detectors placed around the point of scattering.  
Because the angular variation of the scattered light is directly related to the size of the 
molecule, the root mean square radius of the MLVs can be determined using ASTRA 
software that collects the voltages from each detector.  From this, given information 
about the conformation of the scattering particle, the geometric radius of the sample is 
calculated.  This all occurs according to the basic light scattering equation (Rayleigh-
Gans-Debye): 
 
  )](21)[()()( 2
* θθθθ McPAMcPKRI scattered −=∝   (4) 
 
where R(θ) is the excess Raleigh ratio (proportional to intensity of scattered light in 
excess of light scattered by solvent), M is the molar mass, c is the solute concentration, 
P(θ) is the form factor, A2 is the second virial coefficient, and K
*
 is the constant 
 







with no the solvent refractive index, NA Avogadro’s number, λo 




FIGURE 9.  AFFF and MALS setup. 
 
 MLVs were prepared and analyzed by light scattering as described.  The Figure 
below shows the geometric radius of particles passing through the 690 nm beam as a 
function of time. 
 
                                                                                                                                                20 
 
FIGURE 10.  Geometric radii of liposomes passed through 50 and 80 nm membranes. 
 
The MLVs extruded through the 50 nm membrane appear to have geometric radii 
between 70-85 nm, while the MLVs extruded through the 80 nm membrane are in the 80-
100 nm range.  Particles are slightly larger than the membrane through which they are 
extruded due to swelling that occurs as the particles emerge from the membrane.  In order 
to determine the size of the particles from MALS, the ASTRA software uses the coated 
sphere model with the reported dn/dc value of 0.134 for liposomes, the real refractive 
index of 1.33 for the PBS solution within the liposomes, and a coating thickness of 9 nm 
correlating to the size of the lipids surrounding the particle. 
 
Cellular Uptake and Release of BCH 
 
 All cells will be cultured to semiconfluency and 1 mL of the BCH liposomal 
formulation will be added to the culture flasks.  The concentration of BCH in the 
liposomal formulation will be 0, 50, 100, and 150 µg/mL.  Cells will be cultured with the 
added BCH liposomal formulation for 2, 16, and 48 hours at 37
o
C.  Following this 
incubation, cells will be washed three times with 0.01 M D-PBSA, pH 7.4 and 
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disaggregated with tryspin-EDTA.  The BCH retention study will be carried out by 
aspirating the culture medium, replacing it with fresh medium and culturing the cells for 
an additional 24 hours, followed by washing and harvesting the cells as described above. 
 Cellular concentrations of the BCH will be determined using high performance 
liquid chromatography (HPLC).  Once the cells are harvested, BCH in the cells will be 
extracted by a 1:1 (v/v) methanol-isopropanol mixture.  A Zorbax Stable Bond C-18 
column coupled to an Agilent Tech Series 1100/1200 pump and Linear UVIS 204 system 
will be used to analyze the BCH in the cells.  The column is equilibrated with the mobile 
phase consisting of 50% methanol and 50% isopropanol at a flow rate of 0.5 mL/min.  A 
standard solution containing 1 mg of cholesterol, BCH, triolein, cholesteryl oleate, and 
cholesteryl heptadecanoate dissolved in 50 mL of mobile phase solvent will be used as 
calibration.  The UV absorption at the λmax of BCH (220nm) will be detected and used to 
determine the amount of BCH in each cell sample. 
 
Thermal Column Insert Design, Fabrication, and Characterization 
 
 The thermal column (TC) experimental facility will be used to irradiate the cells, 
following adaptations made to the original TC insert plug to accommodate biological 
irradiations.  The original TC insert plug is made of solid concrete and is being replaced 
with an insert plug containing a chamber capable of controlling the environmental 
conditions of the sample.  Environmental control of the sample chamber will be provided 
by a water jacket and CO2 gas lines connected to external sources.  Figure 11 shows a 
schematic of the modified TC insert plug. 
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FIGURE 11.  Schematic of the new TC insert plug. 
 
A CO2 detector and thermocouple embedded in the sample chamber will provide real-
time values for the CO2 concentration and temperature.  The system will be allowed to 
equilibrate once the cells have been placed in the chamber, prior to irradiation.  This will 
allow prolonged irradiations which would otherwise result in non-specific cell death.  In 
addition to this, irradiations will be performed at the optimal growing conditions of the 
cells and will better simulate the physiological response of the cells in vivo.  
 Once the fabrication of the new TC insert plug is complete, beam characterization 
within the sample chamber will be performed.  This will be accomplished through the use 
of paired ion chambers, foil activation, and a tissue equivalent proportional counter 
(TEPC).  Measurements will be taken at various power levels to determine the optimum 
conditions for high thermal neutron flux with minimal contribution from gamma rays.   
 The dual ion chamber technique will be performed with two IC-18, 0.1 cc ion 
chambers (Far West Technology) used in tandem to detect the individual gamma ray and 
neutron contributions to the total dose.  The first chamber, IC-18G, is made of a 0.064 in. 
graphite wall filled with air that is sensitive to gamma rays.  The second chamber, IC-18, 
is made of a 0.064 in. tissue equivalent plastic filled with a gas mixture that approximates 
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the composition of biological tissue (64.4% CH4, 32.4% CO2, 3.2% N2, Airgas) and is 
sensitive to both gamma rays and neutrons.  Ion chambers are not ideal for detection of 
thermal neutrons and will be better served to give an approximation of the contribution of 
epithermal and fast neutrons.   
 In a similar method as described for the IC-18 ion chamber, a SW5 TEPC (Far 
West Technology) will be used to determine the absorbed dose rate at various power 
levels.  The same tissue equivalent gas mixture will be used to fill the chamber 
throughout the irradiation.  A code adapted from the Pacific Northwest National 
Laboratories (PNNL) will be used to convert the data into absorbed dose.   
 In an effort to further unfold the neutron energy spectrum, foil and wire activation 
will be performed.  Foil activation is an indirect detection method that involves inducing 
radioactivity of a particular material by neutron irradiation.  Exposing a foil sample to a 
neutron flux for a specific period of time, followed by counting with a high purity 
germanium detector (HPGe), the number and energy distribution of the neutrons can be 
determined.  The rate of this activation is determined by: 
 
   R = A∞ = φΣactV       (5) 
 
In the above formula, R is the rate of activation, A∞ is the saturated activity, φ is the 
neutron flux, Σact is the activation cross section, and V is the foil volume.  As the foil is 
irradiated, the activity A increases as a function of time according to the equation: 
 
   Ao = A∞(1-e
-λto
)     (6)  
 
where λ is the decay constant and t is time.  It is important to note that the activity of the 
foil will decrease immediately after removal from the neutron beam and therefore foil 
counting must be performed quickly and the time delay must be accounted for.  The 
following figure shows the activity of a sample throughout this process. 
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FIGURE 12.  The activity of a foil throughout and following irradiation. 
 
















εε   (7) 
 
where ε is the counting efficiency and B is the number of background counts.  By 
combining equations 6 and 7 the saturated activity can be determined from equation 8, 













=      (8) 
 
The following foils (Alfa Aeser) will be used:  W, Ti, Fe, Cu, Ni, Co, Al, V, Mg, Sc, Au, 
and In.  For the threshold activation studies, foils will be irradiated alone and then 
irradiated again when wrapped in Cd, In, Ag, and depleted U.  Gold and indium foils are 
especially valuable for the determination of the thermal neutron spectrum.  The following 
tables indicate properties of the materials used for activation detection. 
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Irradiated samples will then be counted using a GC2020 HPGe detector (Canberra) with 
Genie 2000 software and applied to the MXD_FC33 code (Physikalisch-Technische 
Bundesanstalt, Germany) to provide the neutron energy spectrum within the TC. 
 The results will then be compared to the MCNP-5C model that was previously 
written for the University of Maryland research reactor facility.
49
  Radiation surveying at 
various power levels and locations within the reactor has been used to benchmark the 
coded simulation and will be improved as better characterization of the TC experimental 
facility is completed. 
 
 
FIGURE 13.  Simulation of the MUTR with MCNP-5C. 
 
Thermal Neutron Irradiation 
 
 Prior to irradiation, each tissue flask containing BCH will be washed as described 
above and filled with fresh media.  Tissue flasks containing the RWPE-1 and PC-3 cells 
will be transferred to an incubator within the MUTR facility.  The sample chamber within 
the TC insert plug will be set to 37
o
C and 5% CO2 throughout the irradiation.  Each flask 
will be irradiated separately, with matching irradiations performed for normal and cancer 
 
                                                                                                                                                27 
cells.  Cells will be irradiated to 0, 2, 4, 6, and 8 Gy, performed in triplicate for each dose 
and cell type.  Immediately following irradiation, cells will be removed from the TC 
insert plug and transferred to the incubator for the cell survival assay. 
 
Cell Survival Assay 
 
 Following irradiation, media will be aspirated from the tissue flasks and the cells 
will be washed with 8 mL of D-PBSA.  The cells will be detached from the tissue flasks 
by addition of trypsin-EDTA and the cell suspension will then be centrifuged at 125 g for 
6 min.  Cell pellets will be resuspended in fresh media and cell density will be counted 
using a hemocytometer.  Cells will then be diluted to the appropriate cell densities for 
plating.  Ideally, there should be approximately 50 surviving cells per 25 cm
2
 tissue flask.  
Therefore, depending on the plating efficiency of each cell line and the dose delivered to 
the sample, the number of cells plated must be adjusted accordingly.  The cells are then 
incubated at 37
o
C and 5% CO2 for 10-14 days.  This will allow the colonies to grow large 
enough to be seen with the naked eye once stained.  After 10-14 days, the media will be 
aspirated from the cells and the cells will be washed with 8 mL of D-PBSA.  A mixture 
of 5 mL D-PBSA and 5 mL methanol is then used to wash the cells, followed by cell 
fixing with 10 mL of methanol for 10 min.  After aspirating the methanol, 5 mL of 0.1% 
crystal violet solution is added to the cells for 10 min.  The stain solution is then aspirated 




FIGURE 14.  Staining of surviving colonies with crystal violet. 
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 When performing the cell survival assay there are two important factors that must 
be accounted for.  First, the plating efficiency of the cell lines must be determined.  This 
is accomplished by following the same procedure outlined above, but without any 
irradiation.  By simply detaching the cells from one tissue flask and re-plating them in 
another, the viability of cells subjected to such a transfer can be determined.  The plating 
efficiency is used to help determine the number of cells to be plated following irradiation 
and is subtracted out from the overall cell death to isolate cell death that is attributed to 
radiation alone.  Second, the cell death due to gamma ray contribution in the mixed LET 
irradiation must also be accounted for.  To accomplish this, dosimetry will be used to 
identify the gamma ray dose delivered to the cells during irradiation in the TC.  Once this 
has been established for each dose, cell irradiations will be repeated as described above 
using the 124 kCi 
60
Co gamma source.   
 
  
FIGURE 15.  
60
Co gamma source. 
 
Cells will be exposed to the liposomal formulation and then transferred to the gamma cell 
for irradiation.  Calibration of the dose rates within the gamma source has been 
completed with NIST alanine dosimetry, and cells will be irradiated with the same dose 
rates and total dose experienced in the reactor TC.  By conducting cell survival assays 
from these gamma ray irradiations, the mixed LET reactor irradiation can be separated 
into cell death from gamma rays and thermal neutrons (non-specific and specific cell 
death).   
 




 Preparation and analysis of the liposomes containing BCH and plating efficiency 
studies for RWPE-1 and PC-3 cell lines are currently under investigation.  Initial studies 
to measure BCH uptake by the cell lines has begun and will continue for each BCH 
concentration and incubation time throughout the Spring 2008 semester.  Fabrication of 
the TC insert plug has begun and will be completed by March/April.  Immediately 
following completion, beam characterization within the sample chamber will be 
performed and completed by the end of April.  Cell irradiations within the gamma cell 
and MUTR will then begin and carry on throughout the Fall 2008 semester.  Once the 
cell survival assays for each dose has been performed, the next few months will be spent 
submitting final papers and writing my dissertation.  I expect to complete this research 
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